Buscador de publicacions

Publicacions

  • Brown, Elizabeth J., Balaguer-Lluna, Leire, Cribbs, Adam P., Philpott, Martin, Campo, Leticia, Browne, Molly, Wong, Jong Fu, Oppermann, Udo, Carcaboso AM, Bullock, Alex N. and Farnie, Gillian.

    PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo

    SCIENTIFIC REPORTS . 14(1): .

    [doi:10.1038/s41598-023-48652-x]

  • Wiese M, Pohlmeier B, Kubiak K, El-Khouly FE, Sitte M, Carcaboso AM, Baugh JN, Perwein T, Nussbaumer G, Karremann M, Gielen GH, Salinas G and Kramm CM.

    Boswellic acid formulations are not suitable for treatment of pediatric high-grade glioma due to tumor promoting potential

    Journal of Traditional and Complementary Medicine . 14(1): 101-108.

    [doi:10.1016/j.jtcme.2023.07.007]

  • Aschero MR, Ganiewich D, Lamas G, Restrepo-Perdomo CA, Ottaviani D, Zugbi S, Camarero S, Néspoli E, Cuadrado-Vilanova M, Pérez-Jaume S, Pascual-Pastó G, Sampor C, Grigorovski N, Salas B, Suñol M, Carcaboso AM, Mora J, de Dávila MTG, Doz F, Radvanyi F, Abramson DH, Llera AS, Schaiquevich PS, Lubieniecki F and Chantada G.

    Immunohistochemical expression of TFF1 is a marker of poor prognosis in retinoblastoma

    PEDIATRIC BLOOD & CANCER . 71(1): .

    [doi:10.1002/pbc.30717]

  • Zugbi S, Aschero MR, Ganiewich D, Cancela MB, Winter U, Ottaviani D, Sampor C, Dinardi M, Torbidoni AV, Mena M, Balaguer-Lluna L, Lamas G, Sgroi M, Lagomarsino E, Lubieniecki F, Fandiño A, Radvanyi F, Abramson DH, Podhajcer O, Llera AS, Cafferata EG, Chantada G, Carcaboso AM and Schaiquevich P.

    Establishment and Comprehensive Characterization of a Novel Preclinical Platform of Metastatic Retinoblastoma for Therapeutic Developments.

    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE . 64(15): 27-27.

    [doi:10.1167/iovs.64.15.27]

  • Lee K, Yun S, Park J, Lee S, Carcaboso AM, Yi SJ and Kim K.

    Dimethyl alpha-ketoglutarate inhibits proliferation in diffuse intrinsic pontine glioma by reprogramming epigenetic and transcriptional networks

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS . 677: 6-12.

    [doi:10.1016/j.bbrc.2023.07.050]

  • Fanlo, L, Gomez-Gonzalez S, Rozalen, C, Perez-Nunez, I, Sangrador, I, Tomas-Daza, L, Gautier, EL, Usieto, S, Rebollo, E, Vilà-Ubach M, Carcaboso AM, Javierre, BM, Celia-Terrassa, T, Lavarino C, Marti, E and Le Dreau, G.

    Neural crest-related NXPH1/a-NRXN signaling opposes neuroblastoma malignancy by inhibiting organotropic metastasis

    Oncogene . 42(28): 2218-2233.

    [doi:10.1038/s41388-023-02742-2]

  • Mensali, N, Köksal, H, Joaquina, S, Wernhoff, P, Casey, NP, Romecin, P, Panisello, C, Rodriguez, R, Vimeux, L, Juzeniene, A, Myhre, MR, Fåne, A, Ramírez, CC, Maggadottir, SM, Duru, AD, Georgoudaki, AM, Grad, I, Maturana, AD, Gaudernack, G, Kvalheim, G, Carcaboso AM, de Alava, E, Donnadieu, E, Bruland, OS, Menendez, P, Inderberg, EM and Wälchli, S.

    ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma

    NATURE COMMUNICATIONS . 14(1): . Nº de cites: 4

    [doi:10.1038/s41467-023-39097-x]

  • Aschero MR, Castillo H, Baulenas-Farrés M, Resa-Parés C, Jiménez-Cabaco A, Rodriguez E, Monterrubio C, Pérez-Jaume S, Suñol M, Chantada G, Lavarino C, Mora J and Carcaboso AM.

    Prognostic value of xenograft engraftment in patients with metastatic high-risk neuroblastoma

    PEDIATRIC BLOOD & CANCER . 70(6): . Nº de cites: 2

    [doi:10.1002/pbc.30318]

  • Thirant, C, Peltier, A, Durand, S, Kramdi, A, Louis-Brennetot, C, Pierre-Eugene, C, Gautier, M, Costa, A, Grelier, A, Zaïdi S, Gruel, N, Jimenez, I, Lapouble, E, Pierron, G, Sitbon, D, Brisse, HJ, Gauthier, A, Freneaux, P, Grossetête S, Baudrin, LG, Raynal, V, Baulande, S, Bellini, A, Bhalshankar, J, Carcaboso AM, Geoerger, B, Rohrer, H, Surdez, D, Boeva, V, Schleiermacher, G, Delattre, O and Janoueix-Lerosey, I.

    Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma

    NATURE COMMUNICATIONS . 14(1): 2575-2575. Nº de cites: 6

    [doi:10.1038/s41467-023-38239-5]

  • Tucker ER, Jiménez I, Chen L, Bellini A, Gorrini C, Calton E, Gao Q, Che H, Poon E, Jamin Y, Martins Da Costa B, Barker K, Shrestha S, Hutchinson JC, Dhariwal S, Goodman A, Del Nery E, Gestraud P, Bhalshankar J, Iddir Y, Saberi-Ansari E, Saint-Charles A, Geoerger B, Marques Da Costa ME, Pierre-Eugene C, Janoueix-Lerosey I, Decaudin D, Némati F, Carcaboso AM, Surdez D, Delattre O, George SL, Chesler L, Tweddle DA and Schleiermacher G.

    Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models

    CLINICAL CANCER RESEARCH . 29(7): 1317-1331. Nº de cites: 6

    [doi:10.1158/1078-0432.CCR-22-2274]